Biotron, an Australian biotechnology company developing and commercializing novel therapeutics and diagnostics to address a range of significant health issues, has concluded first part of its blinded Phase 2 trial evaluating BIT225, a drug to treat Hepatitis C virus infected patients.
In the first part, Biotron has dosed around 12 patients in the center, dddmag.com reported.
Patients were divided according to the dosing of the drug, in which one-third of the patients were given placebo, another one-third were give 400mg dose of BIT225 and rest of one-third patients were dosed at 200mg BIT225.
Further, Biotron is expecting to examine 12 more patients in the second part of the Phase 2 ongoing trial.
The results of the trial are expected to be released in June 2011.
Dddmag.com has quoted Biotron CEO Michelle Miller as saying that they have achieved the necessary ethics and drug import approvals to move to the second stage of the trial, which is now underway.